4 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow JNJ-55308942: new trials by email Literature Review of JNJ-55308942 trials Research Report on JNJ-55308942
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-55308942 in the Treatment of Bipolar Depression JNJ-55308942, Placebo - Bipolar Disorder | Phase 2 | Completed | Janssen Pharmaceutica N.V., Belgium | 116 | 2022-06-03 | 2025-07-11 |
| A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol JNJ-55308942 High Dose, JNJ-55308942 Low Dose, Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC) - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 14 | 2018-06-08 | 2025-04-27 |
| A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739 JNJ-55308942, [18F]-JNJ-64413739 - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 13 | 2018-03-15 | 2025-04-27 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants JNJ-55308942 0.5 mg, JNJ-55308942 1.5 mg, JNJ-55308942 4 mg - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 98 | 2017-05-03 | 2025-04-27 |
Bipolar Disorder (1)
Janssen-Cilag International NV (3) · Janssen Pharmaceutica N.V., Belgium (1)
Belgium (3) · Canada (1) · Poland (1) · Spain (1) · United States (1)
2017 (2), 2018 (1)